A dose-escalation and dose expansion Phase I clinical study of HQP1351 in patients with Chronic myeloid leukaemia (CML)
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs HQP 1351 (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 14 Nov 2019 According to an Ascentage Pharma media release, Xiaojun Huang, M.D. along with Qian Jiang, M.D., from Peking University People's Hospital are the principal investigators of this study.
- 14 Nov 2019 According to an Ascentage Pharma media release, updated preliminary results from this study has been accepted for oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (7th-10th Dec 2019, in Orlando, Florida, United States).
- 14 Nov 2019 Preliminary results (as of 27th May 2019, n=101) presented in an Ascentage Pharma media release.